peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

Parathyroid hormone analog · PTH(1–34)

Teriparatide

/ter-i-PAR-a-tide/FDA-approved ingredient
Loading scientific anatomy…
Interactive anatomy · drag to rotate

02 · Consumer names

One ingredient.
Distinct products.

01

Forteo

Daily subcutaneous injection

Osteoporosis treatment in specified high-risk populations.

Find official label ↗
02

Bonsity

Daily subcutaneous injection

Teriparatide product with its own device and label.

Find official label ↗
03

Teriparatide injection

Daily subcutaneous injection

Approved generic/alternative presentations vary by manufacturer.

Find official label ↗

Product names are not synonyms for one another. Route, strength, indication, and instructions can differ. Compare with primary label

03 · Mechanism + use

What the molecule does,
and where the label stops.

What it does
Activates PTH1 receptors. Intermittent exposure favors osteoblast activity and new bone formation, increasing skeletal mass and strength.Mechanism source
Labeled-use boundary
Treatment is reserved for specified patients at high fracture risk or those who failed or cannot tolerate other osteoporosis therapy.Primary label

04 · Labeled safety

Risk belongs
beside benefit.

Who should avoid it

  • Serious hypersensitivity; avoid in patients with increased baseline osteosarcoma risk as described in labeling
Contraindications

More common effects

  • Nausea
  • Joint aches
  • Pain
  • Transient dizziness
Adverse reactions

Important serious risks

  • Osteosarcoma risk considerations
  • Hypercalcemia
  • Orthostatic hypotension
  • Urolithiasis considerations
  • Medication/device errors
Warnings

This is a structured label summary, not a complete prescribing-information substitute and not a personalized risk estimate.

05 · Evidence interpretation

Claims with
their edges visible.

01

An anabolic bone strategy

Intermittent PTH1 receptor activation increases bone formation.

Supporting source
Evidence form
Randomized fracture and bone-density trials
Keep in view
Sequence with other osteoporosis therapies affects long-term strategy.
02

Fracture-risk populations

Approved uses center on people at high fracture risk or with limited alternatives.

Supporting source
Evidence form
Outcome-based regulatory evidence
Keep in view
Not a general wellness or performance peptide.
03

Risk context changed over time

Human observational evidence and label updates refine the osteosarcoma discussion.

Supporting source
Evidence form
Regulatory longitudinal review
Keep in view
Avoidance criteria remain important.

06 · Research universe

Reviewed anchors.
Live indexes.

The regulatory label anchors approved use and safety. PubMed and ClinicalTrials.gov expose the broader, continuously changing research universe without pretending every result has been reviewed.

  1. 01Regulatory label
    Forteo prescribing information

    DailyMed label updated June 2025 for teriparatide injection.

    Open source ↗
  2. 02Literature index
    Every PubMed result for teriparatide

    Live National Library of Medicine literature search; results are not pre-screened or deduplicated.

    Open source ↗
  3. 03Trial registry
    Every registered study for teriparatide

    Live ClinicalTrials.gov search, including completed, active, and historical records.

    Open source ↗
  4. 04Chemical record
    teriparatide chemical record

    PubChem compound search from the National Library of Medicine.

    Open source ↗